Reviewing Arcus Biosciences Inc. (RCUS)’s and CASI Pharmaceuticals Inc. (NASDAQ:CASI)’s results

As Biotechnology companies, Arcus Biosciences Inc. (NYSE:RCUS) and CASI Pharmaceuticals Inc. (NASDAQ:CASI) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcus Biosciences Inc. 8.04M 59.04 50.51M -1.18 0.00
CASI Pharmaceuticals Inc. N/A 0.00 23.25M -0.30 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Arcus Biosciences Inc. and CASI Pharmaceuticals Inc.

Profitability

Table 2 provides us Arcus Biosciences Inc. and CASI Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Arcus Biosciences Inc. -628.23% 0% 0%
CASI Pharmaceuticals Inc. 0.00% -30.7% -28.7%

Liquidity

Arcus Biosciences Inc.’s Current Ratio and Quick Ratio are 16 and 16 respectively. The Current Ratio and Quick Ratio of its competitor CASI Pharmaceuticals Inc. are 14.6 and 14.6 respectively. Arcus Biosciences Inc. therefore has a better chance of paying off short and long-term obligations compared to CASI Pharmaceuticals Inc.

Analyst Ratings

In next table is delivered Arcus Biosciences Inc. and CASI Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arcus Biosciences Inc. 0 0 0 0.00
CASI Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, CASI Pharmaceuticals Inc.’s potential upside is 107.72% and its consensus price target is $7.

Institutional and Insider Ownership

Institutional investors owned 40% of Arcus Biosciences Inc. shares and 20.7% of CASI Pharmaceuticals Inc. shares. Arcus Biosciences Inc.’s share owned by insiders are 0.9%. On the other hand, insiders owned about 9.2% of CASI Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arcus Biosciences Inc. 10.68% 12.26% -2.69% -21.59% 0% -25.65%
CASI Pharmaceuticals Inc. -9.93% 2.9% -42.65% -36.17% 18.9% 20%

For the past year Arcus Biosciences Inc. had bearish trend while CASI Pharmaceuticals Inc. had bullish trend.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.